{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"260","value":"24.4"},{"groupId":"OG001","spread":"63.9","value":"24.7"},{"groupId":"OG002","spread":"66.2","value":"23.5"},{"groupId":"OG003","spread":"64.4","value":"27.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"14"}],"units":"Participants"}],"description":"Trough plasma concentrations of Afatinib at Day 43 (course 3, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients received Afatinib monotherapy 20 mg film-coated tablets orally once daily after a dose reduction.","id":"OG000","title":"Afatinib 20 mg"},{"description":"Patients received Afatinib monotherapy 30 mg film-coated tablets orally once daily after a dose reduction.","id":"OG001","title":"Afatinib 30 mg"},{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG002","title":"Afatinib 40 mg"},{"description":"Patients received Afatinib monotherapy 50 mg film-coated tablets orally once daily after a dose escalation.","id":"OG003","title":"Afatinib 50 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Patients from the treated set with evaluable data and who had at least 1 valid Afatinib plasma concentration available on this time point.","reportingStatus":"POSTED","timeFrame":"Day 43.","title":"Trough Plasma Concentrations of Afatinib at Day 43","type":"SECONDARY","unitOfMeasure":"ng/mL."}